Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | SVP, GC & Corp. Sec. | July 05, 2018 | July 09, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date July 05, 2018 · Filed July 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 34,993 |
Reported balance
After 2018-07-05 transaction · row 1
1 source rowRow 1 · 2018-07-05 · Other · Acquired 34,993 · Balance 34,993 F1: Represents a pro rata in-kind distribution of Class A Common Stock by APHC Holdings, LLC to its members who are holders of profit participation units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro rata in-kind distribution of Class A Common Stock by APHC Holdings, LLC to its members who are holders of profit participation units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2018 Filed Jul 9, 2018 21:13 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | OtherClass A Common Stock | 34,993 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019664 · doc4.xml · nonDerivative · entry 1 Hirt Sheldon · CIK 0001647557 · SVP, GC & Corp. Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,993 F1 · kind: Represents a pro rata in-kind distribution of Class A Common Stock by APHC Holdings, LLC to its members who are holders of profit participation units. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:33 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 17,766 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-012147 · doc4.xml · derivative · entry 2 Hirt Sheldon · CIK 0001647557 · SVP, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,766 Underlying: Class A Common Stock · 17,766 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:33 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 72,661 | $0.00 Strike: $15.01 | $0.00 |
DisclosureSEC source: 0000899243-18-012147 · doc4.xml · derivative · entry 1 Hirt Sheldon · CIK 0001647557 · SVP, GC & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,661 Underlying: Class A Common Stock · 72,661 shares Expires 2028-05-07 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on May 07, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.